EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Higher plasma dicarbonyl levels are associated with liver fibrosis in obese individuals

Oluwatomisono I Akinrimisi iD, Mijra Koning, Jean L J M Scheijen iD, Abraham S Meijnikman iD, Daniko P Sindhunata, Sjoerd Bruin, Arnold van de Laar, Rutger Franken, Yair Acherman iD, Victor E A Gerdes, Max Nieuwdorp iD, Casper G Schalkwijk iD und 1 weitere

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16643 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Oluwatomisono I Akinrimisi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Vascular & Internal Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Liver Cirrhosis, Pyruvaldehyde, Obesity, Deoxyglucose. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ERC Advanced Grant, Senior Clinical Dekker grant by the Dutch Heart Foundation, Dutch Gastroenterology and Hepatology Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Methylglyoxal (MGO) is a very reactive compound that modifies proteins, forming advanced glycation end products (AGEs) and activating inflammatory pathways. Elevated MGO levels have been linked to various diseases, including type 2 diabetes and atherosclerosis. However, the role of MGO and other glycating agents in the progression of liver fibrosis in the setting of metabolic dysfunction associated steatotic liver disease (MASLD) is poorly understood.

Methods

This study explores the relationship between plasma MGO levels and related dicarbonyls (glyoxal (GO) and 3‐deoxyglucosone (3‐DG)), which are measured using ultra‐high‐performance liquid chromatography tandem mass spectrometry (UPLC‐MS/MS), and liver fibrosis assessed via histological liver biopsy scoring and the Fibrosis‐4 (FIB‐4) Index. The study population comprised 264 severely obese individuals due to undergo bariatric surgery, a subset from the BARIA cohort (22% type 2 diabetes; 77% females; median age 47 (IQR: 39–54 years); BMI 39 (IQR: 36–41 kg/m 2 )).

Results

MGO levels were significantly higher in individuals with type 2 diabetes compared with individuals without type 2 diabetes, with a median of 288 nmol/L (257–334 nmol/L) and 238 (212–279 nmol/L) respectively. MGO levels were higher in males compared with females, with a median of 267 (236–301 nmol/L) and 245 (214–288 nmol/L) respectively. Similar results were found for GO and 3DG. Higher plasma MGO, GO and 3DG levels were significantly associated with the FIB‐4 Index (MGO, rho = 0.21, p < 0.01), (GO, rho = 0.29, p < 0.01), (3DG, rho = 0.25, p < 0.05). Using linear regression models, the association between MGO and the FIB‐4 Index remained significant after adjustment for age (years), sex, BMI, sub‐cohort, smoking status, alcohol consumption, hypertension, HOMA‐IR, HbA1c and fasting glucose levels. Using ordinal logistic regression models, MGO and GO were also associated with liver fibrosis scoring from biopsy before and after adjustment for confounders (Age (years), sex, BMI, sub‐cohort, smoking status, alcohol consumption, hypertension, HOMA‐IR, HbA1c and fasting glucose levels). Notably, the relationships remained significant in individuals without type 2 diabetes and after adjusting for HbA1c and fasting glucose levels. No significant associations were observed between MGO, GO, or 3DG and steatosis or inflammation histology scores after adjustment for confounders.

Conclusion

This study shows the potential role of dicarbonyl stress, particularly MGO, in liver fibrosis among obese individuals, highlighting its significance as an independent contributor to liver damage and a potential therapeutic target.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisPyruvaldehydeObesityDeoxyglucoseGlyoxalHumansFemaleMaleMiddle AgedAdultDiabetes Mellitus, Type 2BiomarkersLiver

Stichwörter der Autor:innen

dicarbonylsfibrosislivermethylglyoxaltype 2 diabetes

Substanzen

PyruvaldehydeDeoxyglucose3-deoxyglucosoneGlyoxalBiomarkers

Autor:innen und Institutionen

  • Department of Experimental Vascular & Internal Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
  • CARIM, School for Cardiovascular Diseases, Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • Tytgat Institute for Liver and Intestinal Research, Amsterdam University Medical Center, Amsterdam, The Netherlands.
  • Diabeter Center, Amsterdam, The Netherlands.

ORCID-Profile: Oluwatomisono I Akinrimisi, Jean L J M Scheijen, Abraham S Meijnikman, Yair Acherman, Max Nieuwdorp, Casper G Schalkwijk, Nordin M J Hanssen

Förderung

  • ERC Advanced Grant
  • Senior Clinical Dekker grant by the Dutch Heart Foundation
  • Dutch Gastroenterology and Hepatology Foundation
  • ZONMW-VIDI grant 2023
  • NWO VICI grant 2020
  • VENI grant 2023

Zitieren

APA

Akinrimisi, O. I., Koning, M., Scheijen, J. L. J. M., Meijnikman, A. S., Sindhunata, D. P., Bruin, S., van de Laar, A., Franken, R., Acherman, Y., Gerdes, V. E. A., Nieuwdorp, M., Schalkwijk, C. G., & Hanssen, N. M. J. (2025). Higher plasma dicarbonyl levels are associated with liver fibrosis in obese individuals. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16643

Vancouver

Akinrimisi OI, Koning M, Scheijen JLJM, Meijnikman AS, Sindhunata DP, Bruin S, et al. Higher plasma dicarbonyl levels are associated with liver fibrosis in obese individuals. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16643

BibTeX
@article{Akinrimisi2025,
  author = {Akinrimisi, Oluwatomisono I and Koning, Mijra and Scheijen, Jean L J M and Meijnikman, Abraham S and Sindhunata, Daniko P and Bruin, Sjoerd and van de Laar, Arnold and Franken, Rutger and Acherman, Yair and Gerdes, Victor E A and Nieuwdorp, Max and Schalkwijk, Casper G and Hanssen, Nordin M J},
  title = {Higher plasma dicarbonyl levels are associated with liver fibrosis in obese individuals},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16643}
}
Kostenlos starten →